Skip to main content

2018 Third Annual Oncology Guide to New FDA Approvals

Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

By Lisa A. Raedler, PhD, RPh

FDA Approvals, News & Updates

2018 Third Annual Oncology Guide to New FDA Approvals

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, News & Updates

2018 Third Annual Oncology Guide to New FDA Approvals

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

By Lisa A. Raedler, PhD, RPh

FDA Approvals, News & Updates

2018 Third Annual Oncology Guide to New FDA Approvals

Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma

FDA Approvals, News & Updates, Lymphoma

2018 Third Annual Oncology Guide to New FDA Approvals

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

By Lisa A. Raedler, PhD, RPh

FDA Approvals, News & Updates

2018 Third Annual Oncology Guide to New FDA Approvals

Page 2 of 2